Q1 2025 Autolus Therapeutics PLC Earnings Call Transcript

May 8, 2025 / 12:30 PM GMT

Release Date Price: $1.35 (+9.76%)

Transcript 10-Q8-K

Key Points

Positve

Autolus Therapeutics PLC (AUTL) reported $9 million in recognized revenue for Q1 2025, indicating a strong start to the US launch of their product, Okasso.
The company has achieved 90% coverage of total US medical lives, with 39 centers authorized to deliver Okasso, showcasing effective market access and onboarding efforts.
Autolus Therapeutics PLC (AUTL) received conditional marketing authorization from the MHRA in the UK, with plans to engage with NICE for reimbursement and access processes.
The company is planning to expand the number of centers delivering Okasso from 39 to approximately 60 by year-end, aiming for 90% patient access across the US.
Autolus Therapeutics PLC (AUTL) has a strong cash position of $516.6 million at the end of Q1 2025, supporting their ongoing commercialization and clinical trial activities.

Negative

The cost of sales for Q1 2025 was $18 million, exceeding the recognized revenue, indicating high initial costs associated with product delivery and manufacturing.
The company reported a net loss of $70.2 million for Q1 2025, an increase from $52.7 million in the same period in 2024, highlighting ongoing financial challenges.
Selling, general, and administrative expenses increased significantly to $29.5 million in Q1 2025 from $18.2 million in the same period in 2024, driven by increased headcount for US commercialization.
There is uncertainty regarding the impact of the April 1st CMS coding update on revenue recognition, which could affect future financial reporting.
The company faces potential challenges with tariffs and regulatory changes, which could impact their operations and market access strategies.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

AUTL.OQ - Autolus Therapeutics PLC
Q1 2025 Autolus Therapeutics PLC Earnings Call
May 08, 2025 / 12:30PM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Good day and thank you for standing by. Welcome to the Autus first quarter, 2025 financial results conference call. At this time, all participants are in a listen-only mode. After the speaker's presentation, there will be a question answer session. To ask a question during the session, you will need to press 11 on your telephone. You will then hear an automated message advising your hand is raised. To withdraw your question, please press 11 again.

Please be advised that today's conference is being recorded. I would not like to hand the conference over to your speaker today, Amanda Cray, executive director of investor relations. Please go ahead.

-----------------------------------------------------------------

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

7-Day Free Trial · Cancel Anytime

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.